2013
Is research in substance abuse undervalued?
Sindelar JL, Strombotne KL. Is research in substance abuse undervalued? Addiction 2013, 109: 3-4. PMID: 24118168, DOI: 10.1111/add.12334.Peer-Reviewed Original Research
2010
Cost evaluation of evidence-based treatments.
Sindelar JL, Ball SA. Cost evaluation of evidence-based treatments. Addiction Science & Clinical Practice 2010, 5: 44-51. PMID: 22002453, PMCID: PMC3120119.Peer-Reviewed Original Research
2008
Paying for performance: the power of incentives over habits
Sindelar JL. Paying for performance: the power of incentives over habits. Health Economics 2008, 17: 449-451. PMID: 18348117, PMCID: PMC3434678, DOI: 10.1002/hec.1350.Peer-Reviewed Original Research
2007
Willingness to pay for drug rehabilitation: Implications for cost recovery
Bishai D, Sindelar J, Ricketts EP, Huettner S, Cornelius L, Lloyd JJ, Havens JR, Latkin CA, Strathdee SA. Willingness to pay for drug rehabilitation: Implications for cost recovery. Journal Of Health Economics 2007, 27: 959-972. PMID: 18207264, PMCID: PMC2601723, DOI: 10.1016/j.jhealeco.2007.11.007.Peer-Reviewed Original ResearchMeSH KeywordsAdultFemaleFinancing, PersonalHumansInterviews as TopicMaleMiddle AgedPatient Acceptance of Health CareRehabilitationSubstance-Related DisordersClinic Variation in the Cost‐Effectiveness of Contingency Management
Olmstead TA, Sindelar JL, Petry NM. Clinic Variation in the Cost‐Effectiveness of Contingency Management. American Journal On Addictions 2007, 16: 457-460. PMID: 18058410, PMCID: PMC3072219, DOI: 10.1080/10550490701643062.Peer-Reviewed Original ResearchTreatment programs in the National Drug Abuse Treatment Clinical Trials Network
McCarty D, Fuller B, Kaskutas LA, Wendt WW, Nunes EV, Miller M, Forman R, Magruder KM, Arfken C, Copersino M, Floyd A, Sindelar J, Edmundson E. Treatment programs in the National Drug Abuse Treatment Clinical Trials Network. Drug And Alcohol Dependence 2007, 92: 200-207. PMID: 17875368, PMCID: PMC2223274, DOI: 10.1016/j.drugalcdep.2007.08.004.Peer-Reviewed Original ResearchMeSH KeywordsAccreditationAlcoholismAnalysis of VarianceConfidentialityData Interpretation, StatisticalHealth Care SurveysHeroin DependenceHumansMethadoneModels, OrganizationalNarcoticsPhilosophy, MedicalQuality Assurance, Health CareResidential TreatmentSubstance Abuse Treatment CentersSubstance-Related DisordersUnited StatesWorkforceConceptsClinical Trials NetworkNational Drug Abuse Treatment Clinical Trials NetworkDrug disordersCommunity-based treatment organizationsTreatment programTrials NetworkSubstance abuse treatment servicesPatient drug useInpatient treatment unitMental health clinicsLevel of careDrug abuse treatment programsCo-occurring conditionsSelf-help meetingsPatient demographicsHealth clinicsTreatment centersTreatment servicesDrug useTreatment philosophyMedical settingsTreatment organizationsVocational servicesNational surveyUniversity-based research centerCost‐effectiveness of prize‐based contingency management in methadone maintenance treatment programs
Sindelar JL, Olmstead TA, Peirce JM. Cost‐effectiveness of prize‐based contingency management in methadone maintenance treatment programs. Addiction 2007, 102: 1463-1471. PMID: 17645428, PMCID: PMC3072844, DOI: 10.1111/j.1360-0443.2007.01913.x.Peer-Reviewed Original ResearchMeSH KeywordsCost-Benefit AnalysisCounselingFemaleHumansMaleMethadoneNarcoticsPatient Acceptance of Health CareRewardSubstance-Related DisordersTreatment OutcomeConceptsPrize-based contingency managementUsual careContingency managementStimulant-negative urine samplesUrine samplesNational Drug Abuse Treatment Clinical Trials NetworkTreatment programMethadone maintenance treatment programIncremental costBaseline urine samplesMulti-site clinical trialMaintenance treatment programMethadone maintenance clinicsClinical Trials NetworkCommunity treatment programsCost-effectiveness studiesCost of treatmentCost-effectiveness analysisPresence of stimulantsCM conditionClinical trialsCommunity clinicsMaintenance clinicsEffectiveness trialTreatment outcomesWhy are Recovering Substance Abuse Counselors Paid Less?
Olmstead TA, Johnson JA, Roman PM, Sindelar JL. Why are Recovering Substance Abuse Counselors Paid Less? Substance Abuse 2007, 28: 31-44. PMID: 19263560, DOI: 10.1300/j465v28n01_05.Peer-Reviewed Original ResearchDirect Care Workers in the National Drug Abuse Treatment Clinical Trials Network: Characteristics, Opinions, and Beliefs
McCarty D, Fuller BE, Arfken C, Miller M, Nunes EV, Edmundson E, Copersino M, Floyd A, Forman R, Laws R, Magruder KM, Oyama M, Prather K, Sindelar J, Wendt WW. Direct Care Workers in the National Drug Abuse Treatment Clinical Trials Network: Characteristics, Opinions, and Beliefs. Psychiatric Services 2007, 58: 181-190. PMID: 17287373, PMCID: PMC2861362, DOI: 10.1176/ps.2007.58.2.181.Peer-Reviewed Original ResearchAdultAge FactorsAlcoholismAttitude of Health PersonnelBehavior TherapyClinical Trials as TopicCognitive Behavioral TherapyCultureData CollectionDiffusion of InnovationEducational StatusEthnicityEvidence-Based MedicineFemaleHealth Knowledge, Attitudes, PracticeHumansMaleMiddle AgedPatient Care TeamProfessional CompetenceProfessional-Patient RelationsPsychotropic DrugsSex FactorsSocioeconomic FactorsSubstance Abuse Treatment CentersSubstance-Related DisordersUnited StatesEquity In Private Insurance Coverage For Substance Abuse: A Perspective On Parity
Barry CL, Sindelar JL. Equity In Private Insurance Coverage For Substance Abuse: A Perspective On Parity. Health Affairs 2007, 26: w706-w716. PMID: 17956926, PMCID: PMC3072843, DOI: 10.1377/hlthaff.26.6.w706.Peer-Reviewed Original ResearchMeSH KeywordsHealthcare DisparitiesHumansInsurance CoverageInsurance, PsychiatricMedical IndigencyMental Health ServicesPoliticsSocial JusticeSubstance-Related DisordersUnited States
2006
Cost-effectiveness of prize-based incentives for stimulant abusers in outpatient psychosocial treatment programs
Olmstead TA, Sindelar JL, Petry NM. Cost-effectiveness of prize-based incentives for stimulant abusers in outpatient psychosocial treatment programs. Drug And Alcohol Dependence 2006, 87: 175-182. PMID: 16971054, PMCID: PMC1950254, DOI: 10.1016/j.drugalcdep.2006.08.012.Peer-Reviewed Original ResearchConceptsUsual careStimulant abusersClinical trialsPatient outcomesNational Drug Abuse Treatment Clinical Trials NetworkDrug abuse treatment clinicsAbstinence-based incentivesIncremental cost-effectiveness ratioUsual care groupPrimary patient outcomeRandomized clinical trialsClinical Trials NetworkPsychosocial treatment programCost-effectiveness ratioCost-effectiveness analysisCare groupTreatment clinicsStimulant abstinenceAcceptability curvesAbstinence timeTreatment programTrials NetworkIncremental costCareIncentive group
2005
What are the correlates of substance abuse treatment counselor salaries?
Olmstead TA, Johnson JA, Roman PM, Sindelar JL. What are the correlates of substance abuse treatment counselor salaries? Journal Of Substance Use And Addiction Treatment 2005, 29: 181-189. PMID: 16183467, DOI: 10.1016/j.jsat.2005.06.001.Peer-Reviewed Original ResearchCounselingHumansSalaries and Fringe BenefitsSubstance Abuse Treatment CentersSubstance-Related DisordersUnited StatesThe role of depression symptoms in predicting drug abstinence in outpatient substance abuse treatment
Dodge R, Sindelar J, Sinha R. The role of depression symptoms in predicting drug abstinence in outpatient substance abuse treatment. Journal Of Substance Use And Addiction Treatment 2005, 28: 189-196. PMID: 15780549, DOI: 10.1016/j.jsat.2004.12.005.Peer-Reviewed Original ResearchMeSH KeywordsAdultAmbulatory CareComorbidityConnecticutCross-Sectional StudiesDepressionFemaleFinancing, GovernmentHumansMaleMiddle AgedMotivationPatient CompliancePatient DischargePublic AssistanceRegression AnalysisSecondary PreventionSocioeconomic FactorsSubstance Abuse DetectionSubstance-Related DisordersTreatment OutcomeConceptsLength of staySubstance abuse treatment outcomesOutpatient substance abuse treatmentSubstance abuse treatmentDepressive symptomsInsurance statusTreatment outcomesAbstinence statusDepression symptomsDrug useDrug abstinenceAbuse treatmentReal-world clinical settingHigher depressive symptom scoresOutpatient substance abuse treatment programsDepressive symptom scoresSubstance abuse treatment programsSymptom scoresTreatment characteristicsPrimary drugDecreased likelihoodReferral sourceClinical settingSymptomsTreatment program
2004
Creating an aggregate outcome index: Cost-effectiveness analysis of substance abuse treatment
Sindelar J, Jofre-Bonet M. Creating an aggregate outcome index: Cost-effectiveness analysis of substance abuse treatment. The Journal Of Behavioral Health Services & Research 2004, 31: 229-241. PMID: 15263863, DOI: 10.1007/bf02287287.Peer-Reviewed Original ResearchMeSH KeywordsCost-Benefit AnalysisData CollectionHumansOutcome Assessment, Health CarePhiladelphiaSubstance-Related DisordersUnited KingdomThe Impact of Managed Care on Substance Abuse Treatment Services
Olmstead T, White WD, Sindelar J. The Impact of Managed Care on Substance Abuse Treatment Services. Health Services Research 2004, 39: 319-344. PMID: 15032957, PMCID: PMC1361010, DOI: 10.1111/j.1475-6773.2004.00230.x.Peer-Reviewed Original ResearchMeSH KeywordsAIDS SerodiagnosisData CollectionHealth Services AccessibilityHealth Services ResearchHumansManaged Care ProgramsMedicareSubstance Abuse Treatment CentersSubstance-Related DisordersConceptsSubstance abuse treatment servicesArea Resource FileSAT facilitiesTreatment servicesTreatment effectivenessImportant public health concernSubstance abuse treatment facilitiesPublic health concernSubstance abuse assessmentRelapse prevention groupPrevention groupPatient needsTypes of servicesCare activitiesInfectious diseasesHealth concernAbuse assessmentCareManaged CareResource FileTesting servicesNational surveyMedical testingRange of servicesInvolvementCost-effectiveness analysis of addiction treatment: paradoxes of multiple outcomes
Sindelar JL, Jofre-Bonet M, French MT, McLellan AT. Cost-effectiveness analysis of addiction treatment: paradoxes of multiple outcomes. Drug And Alcohol Dependence 2004, 73: 41-50. PMID: 14687958, DOI: 10.1016/j.drugalcdep.2003.09.002.Peer-Reviewed Original ResearchMeSH KeywordsAdultAlcoholismAmbulatory CareCase ManagementData CollectionData Interpretation, StatisticalFemaleFinancing, GovernmentFollow-Up StudiesHumansIllicit DrugsMaleOutcome and Process Assessment, Health CarePhiladelphiaPrepaid Health PlansRehabilitationRehabilitation, VocationalReproducibility of ResultsSocial AdjustmentSocial WorkSubstance-Related DisordersUrban Health ServicesConceptsCost-effectiveness analysisDrug Abuse Treatment Cost Analysis ProgramCost-benefit analysisCost-effectiveness ratioEmpirical examplePolicy inferencesEconomic analysisEconomic evaluationConflicting implicationsCost dataPaper identifiesMethodological principlesVariety of outcomesMultiple outcomesRange of outcomesSingle outcomeDifferent outcomesEmploymentAppropriate approachImplicationsParadox
2002
Benefit‐Cost Analysis of Addiction Treatment: Methodological Guidelines and Empirical Application Using the DATCAP and ASI
French MT, Salomé HJ, Sindelar JL, McLellan AT. Benefit‐Cost Analysis of Addiction Treatment: Methodological Guidelines and Empirical Application Using the DATCAP and ASI. Health Services Research 2002, 37: 433-455. PMID: 12036002, PMCID: PMC1430361, DOI: 10.1111/1475-6773.031.Peer-Reviewed Original ResearchConceptsDrug Abuse Treatment Cost Analysis ProgramBenefit-cost analysisEconomic evaluationEconomic benefitsFuture economic researchTotal economic benefitTotal economic costFuture economic evaluationsEconomic researchDetailed methodological guidelinesEmpirical applicationConsecutive fiscal yearsSensitivity analysisOutpatient drug-free programsEconomic costsMethodological guidelinesFiscal yearCost dataSubsequent sensitivity analysisDrug-free programsResource useMethodological foundationsBenefitsCostEstimates
2001
INNOVATIONS IN TREATMENT FOR DRUG ABUSE: Solutions to a Public Health Problem
Sindelar J, Fiellin D. INNOVATIONS IN TREATMENT FOR DRUG ABUSE: Solutions to a Public Health Problem. Annual Review Of Public Health 2001, 22: 249-272. PMID: 11274521, DOI: 10.1146/annurev.publhealth.22.1.249.ChaptersMeSH KeywordsCost-Benefit AnalysisDelivery of Health CareDrug TherapyHumansMotivationOpioid-Related DisordersPrisonersPsychotherapyPublic HealthSubstance-Related DisordersUnited StatesConceptsPublic health problemEffectiveness of treatmentIllicit drug useDrug useHealth problemsDrug dependenceBroader social costsImportant public health problemNew pharmacological agentsFuture treatment programsIndividual functioningStandard treatmentPharmacological agentsTreatment programDrug abuseCounseling strategiesPrevention effortsHigh dropout rateTreatmentFunctioningCompletion ratesDropout rateLow completion ratesLow effectivenessNew setting
2000
Can the Treatment Services Review be used to estimate the costs of addiction and ancillary services?
French M, Roebuck M, McLellan A, Sindelar J. Can the Treatment Services Review be used to estimate the costs of addiction and ancillary services? Journal Of Substance Abuse 2000, 12: 341-361. PMID: 11452838, DOI: 10.1016/s0899-3289(01)00058-x.Peer-Reviewed Original ResearchConceptsUnit cost estimatesCosts of addictionCost estimatesTreatment Services ReviewEconomic evaluation purposesAncillary servicesEconomic cost analysisBenefit-cost ratioCost analysis methodCost analysisComprehensive cost analysisFinancial informationEconomic costsService utilization informationCost analysis toolEstimation purposesService delivery unitsCostUtilization informationFuture evaluation studiesService measuresEstimatesPolicymakersServicesEvaluation study
1991
Economic cost of illicit drug studies: critique and research agenda.
Sindelar JL. Economic cost of illicit drug studies: critique and research agenda. NIDA Research Monograph 1991, 113: 33-45. PMID: 1762641.Peer-Reviewed Original Research